Journal article
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Abstract
Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the first of two independent stages, 50 patients with advanced non-small cell lung cancer received pembrolizumab as standard of care. The primary objectives of stage 1 were to ascertain ctDNA …
Authors
Anagnostou V; Ho C; Nicholas G; Juergens RA; Sacher A; Fung AS; Wheatley-Price P; Laurie SA; Levy B; Brahmer JR
Journal
Nature Medicine, Vol. 29, No. 10, pp. 2559–2569
Publisher
Springer Nature
Publication Date
October 2023
DOI
10.1038/s41591-023-02598-9
ISSN
1078-8956